296 related articles for article (PubMed ID: 27311933)
21. [The application of a new prognostic score system for 435 cases of primary myelodysplastic syndrome diagnosed with WHO classification].
Wang XQ;
Zhonghua Nei Ke Za Zhi; 2009 Aug; 48(8):633-7. PubMed ID: 19954053
[TBL] [Abstract][Full Text] [Related]
22. Dynamic prognostic value of the revised international prognostic scoring system following pretransplant hypomethylating treatment in myelodysplastic syndrome.
Yahng SA; Jeon YW; Yoon JH; Shin SH; Lee SE; Choi YS; Kim DY; Lee JH; Cho BS; Eom KS; Lee S; Min CK; Kim HJ; Lee JW; Lee KH; Min WS; Lee JH; Kim YJ
Bone Marrow Transplant; 2017 Apr; 52(4):522-531. PubMed ID: 27892952
[TBL] [Abstract][Full Text] [Related]
23. Validation of the Revised International Prognostic Scoring System for patients with myelodysplastic syndromes.
Savic A; Marisavljevic D; Kvrgic V; Stanisavljevic N
Acta Haematol; 2014; 131(4):231-8. PubMed ID: 24335346
[TBL] [Abstract][Full Text] [Related]
24. Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?
Zeidan AM; Sekeres MA; Wang XF; Al Ali N; Garcia-Manero G; Steensma DP; Roboz G; Barnard J; Padron E; DeZern A; Maciejewski JP; List AF; Komrokji RS;
Am J Hematol; 2015 Nov; 90(11):1036-40. PubMed ID: 26284571
[TBL] [Abstract][Full Text] [Related]
25. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes.
Bejar R; Stevenson KE; Caughey BA; Abdel-Wahab O; Steensma DP; Galili N; Raza A; Kantarjian H; Levine RL; Neuberg D; Garcia-Manero G; Ebert BL
J Clin Oncol; 2012 Sep; 30(27):3376-82. PubMed ID: 22869879
[TBL] [Abstract][Full Text] [Related]
26. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM).
Della Porta MG; Tuechler H; Malcovati L; Schanz J; Sanz G; Garcia-Manero G; Solé F; Bennett JM; Bowen D; Fenaux P; Dreyfus F; Kantarjian H; Kuendgen A; Levis A; Cermak J; Fonatsch C; Le Beau MM; Slovak ML; Krieger O; Luebbert M; Maciejewski J; Magalhaes SM; Miyazaki Y; Pfeilstöcker M; Sekeres MA; Sperr WR; Stauder R; Tauro S; Valent P; Vallespi T; van de Loosdrecht AA; Germing U; Haase D; Greenberg PL; Cazzola M
Leukemia; 2015 Jul; 29(7):1502-13. PubMed ID: 25721895
[TBL] [Abstract][Full Text] [Related]
27. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.
Zeidan AM; Sekeres MA; Garcia-Manero G; Steensma DP; Zell K; Barnard J; Ali NA; Zimmerman C; Roboz G; DeZern A; Nazha A; Jabbour E; Kantarjian H; Gore SD; Maciejewski JP; List A; Komrokji R;
Leukemia; 2016 Mar; 30(3):649-57. PubMed ID: 26464171
[TBL] [Abstract][Full Text] [Related]
28. Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes.
Lee YJ; Park SW; Lee IH; Ahn JS; Kim HJ; Chung JS; Shin HJ; Lee WS; Lee SM; Joo YD; Kim H; Lee HS; Kim YS; Cho YY; Moon JH; Sohn SK
Ann Hematol; 2016 Oct; 95(11):1795-804. PubMed ID: 27530461
[TBL] [Abstract][Full Text] [Related]
29. Prognostic evaluation of ALIP and CD34 immunostaining in IPSS-R subgroups of myelodysplastic syndromes.
Xiong B; Nie Y; Tang Z; Xue M; Zuo X
Pathology; 2017 Aug; 49(5):526-533. PubMed ID: 28669578
[TBL] [Abstract][Full Text] [Related]
30. Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes.
Efficace F; Cottone F; Abel G; Niscola P; Gaidano G; Bonnetain F; Anota A; Caocci G; Cronin A; Fianchi L; Breccia M; Stauder R; Platzbecker U; Palumbo GA; Luppi M; Invernizzi R; Bergamaschi M; Borin L; Di Tucci AA; Zhang H; Sprangers M; Vignetti M; Mandelli F
Cancer; 2018 Mar; 124(6):1251-1259. PubMed ID: 29231969
[TBL] [Abstract][Full Text] [Related]
31. Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study.
Valcárcel D; Sanz G; Ortega M; Nomdedeu B; Luño E; Diez-Campelo M; Ardanaz MT; Pedro C; Montoro J; Collado R; Andreu R; Marco V; Cedena MT; de Paz R; Tormo M; Xicoy B; Ramos F; Bargay J; Gonzalez B; Brunet S; Muñoz JA; Gomez V; Bailén A; Sanchez J; Merchán B; del Cañizo C; Vallespí T;
Lancet Haematol; 2015 Jun; 2(6):e260-6. PubMed ID: 26688236
[TBL] [Abstract][Full Text] [Related]
32. Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group.
Ramos F; Robledo C; Pereira A; Pedro C; Benito R; de Paz R; Del Rey M; Insunza A; Tormo M; Díez-Campelo M; Xicoy B; Salido E; Sánchez-Del-Real J; Arenillas L; Florensa L; Luño E; Del Cañizo C; Sanz GF; María Hernández-Rivas J;
Am J Hematol; 2017 Sep; 92(9):E534-E541. PubMed ID: 28612357
[TBL] [Abstract][Full Text] [Related]
33. [Study on prognostic significances of different cytogenetic risk categories in patients with primary myelodysplastic syndromes].
Qu SQ; Liu XP; Xu ZF; Zhang Y; Qin TJ; Zhang TJ; Cui R; Hao YS; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):819-24. PubMed ID: 22339954
[TBL] [Abstract][Full Text] [Related]
34. Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories.
Falantes JF; Calderón C; Márquez Malaver FJ; Alonso D; Martín Noya A; Carrillo E; Martino ML; Montero I; González J; Parody R; Espigado I; Pérez-Simón JA
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):144-52. PubMed ID: 23137720
[TBL] [Abstract][Full Text] [Related]
35. Validation of the Lower-Risk MD Anderson Prognostic Scoring System for Patients With Myelodysplastic Syndrome.
Komrokji R; Ramadan H; Al Ali N; Corrales-Yepez M; Zhang L; Padron E; Lancet J; List A
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S60-3. PubMed ID: 26297280
[TBL] [Abstract][Full Text] [Related]
36. Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults.
Fega KR; Abel GA; Motyckova G; Sherman AE; DeAngelo DJ; Steensma DP; Galinsky I; Wadleigh M; Stone RM; Driver JA
J Geriatr Oncol; 2015 Jul; 6(4):288-98. PubMed ID: 26073533
[TBL] [Abstract][Full Text] [Related]
37. Impacts of cytogenetic categories in the Revised International Prognostic Scoring System on the prognosis of primary myelodysplastic syndromes: results of a single-center study.
Qu S; Xu Z; Zhang Y; Qin T; Zhang T; Cui R; Xiao Z
Leuk Lymphoma; 2012 May; 53(5):940-6. PubMed ID: 22023524
[TBL] [Abstract][Full Text] [Related]
38. Mutations and prognosis in myelodysplastic syndromes: karyotype-adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model.
Gangat N; Mudireddy M; Lasho TL; Finke CM; Nicolosi M; Szuber N; Patnaik MM; Pardanani A; Hanson CA; Ketterling RP; Tefferi A
Am J Hematol; 2018 May; 93(5):691-697. PubMed ID: 29417633
[TBL] [Abstract][Full Text] [Related]
39. Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R.
Tefferi A; Lasho TL; Patnaik MM; Saeed L; Mudireddy M; Idossa D; Finke C; Ketterling RP; Pardanani A; Gangat N
Am J Hematol; 2017 Dec; 92(12):1311-1317. PubMed ID: 28875545
[TBL] [Abstract][Full Text] [Related]
40. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System.
Kantarjian H; O'Brien S; Ravandi F; Cortes J; Shan J; Bennett JM; List A; Fenaux P; Sanz G; Issa JP; Freireich EJ; Garcia-Manero G
Cancer; 2008 Sep; 113(6):1351-61. PubMed ID: 18618511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
